Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination regimen consisting of four antimicrobial agents—amphotericin B, cefotaxime, ciprofloxacin, and metronidazole. Each drug has a distinct mechanism of action and spectrum of activity: - **Amphotericin B** is an antifungal agent that binds to ergosterol in fungal cell membranes, creating pores that lead to cell death. It is used for severe systemic fungal infections[1]. - **Cefotaxime** is a third-generation cephalosporin antibiotic with broad-spectrum activity against Gram-positive and Gram-negative bacteria by inhibiting bacterial cell wall synthesis[3]. - **Ciprofloxacin** is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication in susceptible bacteria[9]. - **Metronidazole** is an antiprotozoal and antibacterial agent effective against anaerobic bacteria and certain parasites; it disrupts DNA synthesis after reduction within the microorganism[6]. This combination would provide very broad coverage against fungi (especially yeasts), aerobic Gram-positive/negative bacteria (including many Enterobacteriaceae), anaerobes (including Bacteroides species), as well as some protozoa. Such regimens may be considered in cases of severe mixed infections or empiric therapy for life-threatening intra-abdominal or immunocompromised host infections where polymicrobial etiology—including resistant organisms—is suspected.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amphotericin b + cefotaxime + ciprofloxacin + metronidazole.